InvestSMART

Telix Pharmaceuticals Limited (ASX: TLX) - Announcements

Current share price for TLX : $16.160 0.54 (3.46%)+

ASX company news and announcements for Telix Pharmaceuticals Limited (TLX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Telix Pharmaceuticals Limited (TLX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Telix Pharmaceuticals Limited (TLX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Telix Pharmaceuticals Limited (TLX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$5,491 Share Purchase Plan extended to Friday 25 February 2022 9 Feb 2022 8:22AM $6.970 $16.160 risen by 131.85%
$5,491 Cleansing Notice under S708A(5)(e) Corporations Act 2001 8 Feb 2022 8:31AM $6.810 $16.160 risen by 137.30%
$5,491 Application for quotation of securities - TLX 8 Feb 2022 8:28AM $6.810 $16.160 risen by 137.30%
$5,491 Telix Granted Illuccix EU Regulatory Review Extension 7 Feb 2022 8:31AM $6.810 $16.160 risen by 137.30%
$5,491 ZSP:Sydney Airport to be removed from the S&P/ASX 200 Index 3 Feb 2022 5:37PM $7.190 $16.160 risen by 124.76%
$5,491 Application for quotation of securities - TLX 3 Feb 2022 3:43PM $7.120 $16.160 risen by 126.97%
$5,491 Notice of change of interests of substantial holder 3 Feb 2022 3:41PM $7.120 $16.160 risen by 126.97%
$5,491 Appendix 3Y - C Behrenbruch - exercise of options 3 Feb 2022 3:37PM $7.120 $16.160 risen by 126.97%
$5,491 Telix Full Year Results and Investor Conference Call details 3 Feb 2022 9:40AM $7.450 $16.160 risen by 116.91%
$5,491 Despatch of SPP Booklet to Eligible Shareholders 31 Jan 2022 8:30AM $6.240 $16.160 risen by 158.97%
$5,491 App 3Y Change of Directors Interest Notice - A Kluge 31 Jan 2022 8:30AM $6.240 $16.160 risen by 158.97%
$5,491 Notice of change of interests of substantial holder 31 Jan 2022 8:29AM $6.240 $16.160 risen by 158.97%
$5,491 Cleansing Notice under S708A(5)(e) Corporations Act 2001 31 Jan 2022 8:29AM $6.240 $16.160 risen by 158.97%
$5,491 Notice of change of interests of substantial holder 31 Jan 2022 8:29AM $6.240 $16.160 risen by 158.97%
$5,491 Application for quotation of securities - TLX 31 Jan 2022 8:29AM $6.240 $16.160 risen by 158.97%
$5,491 App 3Y Change of Directors Interest Notice - C Behrenbruch 31 Jan 2022 8:29AM $6.240 $16.160 risen by 158.97%
$5,491 Cleansing Notice under S708A(5)(e) Corporations Act 2001 28 Jan 2022 10:00AM $6.430 $16.160 risen by 151.32%
$5,491 Application for quotation of securities - TLX 27 Jan 2022 12:01PM $6.630 $16.160 risen by 143.74%
$5,491 1st Patient Dosed ProstACT Prostate Cancer Therapy Program 27 Jan 2022 8:22AM $6.620 $16.160 risen by 144.11%
$5,491 Proposed issue of securities - TLX 24 Jan 2022 9:00AM $8.090 $16.160 risen by 99.75%
$5,491 Appendix 4C and Activities Report for December 2021 Quarter 24 Jan 2022 8:59AM $8.090 $16.160 risen by 99.75%
$5,491 Capital Raise Presentation 24 Jan 2022 8:59AM $8.090 $16.160 risen by 99.75%
$5,491 Telix completes $175M placement and launches $25M SPP 24 Jan 2022 8:58AM $8.090 $16.160 risen by 99.75%
$5,491 Trading Halt 20 Jan 2022 8:39AM $8.090 $16.160 risen by 99.75%
$5,491 Investor Presentation to JP Morgan Healthcare Conference 11 Jan 2022 9:43AM $8.170 $16.160 risen by 97.80%

551 - 575 of 951 results

Page 23 of 39

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.